Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2023.0197
Abstract: Importance Platinum-based chemotherapy has been the standard of care for ovarian cancer for the past 3 decades. Although most patients respond to platinum-based treatment, emergence of platinum resistance in recurrent ovarian cancer is inevitable during… read more here.
Keywords: platinum resistant; ovarian cancer; treatment; resistant ovarian ... See more keywords
The Application of Biomaterials in the Treatment of Platinum‐Resistant Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2019 at "ChemMedChem"
DOI: 10.1002/cmdc.201900450
Abstract: More than 70 % of women with ovarian cancer are diagnosed with advanced‐stage disease, which is initially treated with cytoreductive surgery, and combination chemotherapy with platinum‐based compounds. Most patients initially respond to platinum‐based therapy, but eventually… read more here.
Keywords: resistant ovarian; platinum; platinum based; ovarian cancer ... See more keywords
Mithplatins: Mithramycin SA‐Pt(II) Complex Conjugates for the Treatment of Platinum‐Resistant Ovarian Cancers
Sign Up to like & getrecommendations! Published in 2022 at "ChemMedChem"
DOI: 10.1002/cmdc.202200368
Abstract: DNA coordinating platinum (Pt) containing compounds cisplatin and carboplatin have been used for the treatment of ovarian cancer therapy for four decades. However, recurrent Pt‐resistant cancers are a major cause of mortality. To combat Pt‐resistant… read more here.
Keywords: dna; ovarian cancers; ovarian cancer; resistant ovarian ... See more keywords
The effect of FASN inhibition on the growth and metabolism of a cisplatin‐resistant ovarian carcinoma model
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Cancer"
DOI: 10.1002/ijc.31392
Abstract: Overexpression of fatty acid synthase (FASN), a key regulator of the de novo synthesis of fatty acids, has been demonstrated in a variety of cancers and is associated with poor prognosis and increased multidrug resistance.… read more here.
Keywords: resistant ovarian; cisplatin resistant; metabolism; treatment ... See more keywords
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer
Sign Up to like & getrecommendations! Published in 2018 at "Investigational New Drugs"
DOI: 10.1007/s10637-018-0688-4
Abstract: SummaryPurpose To determine the maximum tolerated dose (MTD) of F14512, a topoisomerase II inhibitor designed to target cancer cells through the polyamine transport system, (three-hour daily infusion given for 3 consecutive days every 3 weeks) in… read more here.
Keywords: topoisomerase inhibitor; resistant ovarian; study; platinum refractory ... See more keywords
New approaches for targeting platinum-resistant ovarian cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Seminars in cancer biology"
DOI: 10.1016/j.semcancer.2020.08.013
Abstract: Platinum is the backbone of systemic treatment in ovarian cancer and development of platinum resistance is associated with poor survival. Here, we perform a comprehensive review of the literature regarding resistance mechanisms and advances in… read more here.
Keywords: platinum; resistant ovarian; resistance; ovarian cancer ... See more keywords
Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic Oncology"
DOI: 10.1016/s0090-8258(21)00758-7
Abstract: Objectives: Anlotinib is a novel multi-target tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A previous retrospective study achieved the overall response rate (ORR) of 14.3% and the disease control rate (DCR) of 85.7%… read more here.
Keywords: resistant ovarian; combined pemetrexed; anlotinib combined; ovarian cancer ... See more keywords
Short divalent ethacrynic amides as pro-inhibitors of glutathione S-transferase isozyme Mu and potent sensitisers of cisplatin-resistant ovarian cancers
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Enzyme Inhibition and Medicinal Chemistry"
DOI: 10.1080/14756366.2022.2038591
Abstract: Abstract The linking of ethacrynic acid with ethylenediamine and 1,4-butanediamine gave EDEA and BDEA, respectively, as membrane-permeable divalent pro-inhibitors of glutathione S-transferase (GST). Their divalent glutathione conjugates showed subnanomolar inhibition and divalence-binding to GSTmu (GSTM)… read more here.
Keywords: inhibitors glutathione; glutathione transferase; pro inhibitors; ovarian cancers ... See more keywords
Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx229
Abstract: Background Women with platinum-resistant ovarian cancer are a heterogeneous group whose median overall survival is 12 months. We hypothesized that their quality of life (QoL) scores would be prognostic. Patients and methods Data from AURELIA (n = 326),… read more here.
Keywords: resistant ovarian; function; ovarian cancer; platinum resistant ... See more keywords
ISG15 is downregulated by KLF12 and implicated in maintenance of cancer stem cell‐like features in cisplatin‐resistant ovarian cancer
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.16503
Abstract: Drug resistance is often developed during clinical chemotherapy of ovarian cancers. The ubiquitin‐like protein interferon‐stimulated gene 15 (ISG15) is possibly dependent on tumour context to promote or suppress progression of various tumours. The ubiquitin‐like protein… read more here.
Keywords: resistant ovarian; cisplatin resistant; isg15; ovarian cancer ... See more keywords
PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps5612
Abstract: TPS5612Background: Patients with platinum-resistant ovarian cancer, following ≥3 lines of chemotherapy have limited treatment options. NUC-1031, a phosphoramidate transformation of gemcitabine, is ... read more here.
Keywords: resistant ovarian; nuc 1031; ovarian cancer; platinum resistant ... See more keywords